This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!

05/19/15 - 04:42 PM EDT

Sarepta Therapeutics received the green light from U.S. regulators to finally file a new drug application for eteplirsen, the company's experimental therapy for Duchenne muscular dystrophy.

READ FULL POST

An Open Letter to Sell-Sider Backtracking on Kite Pharma Questions

05/19/15 - 12:48 PM EDT

There's nothing wrong with being a biotech bull who can also raise legitimate questions and understand risks.

READ FULL POST

Investors Get Teary Over Eleven Biotherapeutics' Dry-Eye Drug Failure

05/18/15 - 08:06 AM EDT

Eleven Biotherapeutics' stock price is poised to plummet Monday in the wake of a late-stage study failure of an experimental drug to treat dry eye disease.

READ FULL POST

Amgen Indulges in Another Rheumatoid Arthritis Drug Price Increase

05/05/15 - 02:43 PM EDT

The hike in Enbrel's list price pushed through by Amgen illustrates again how drug companies profit by raising the cost of their older medicines to offset falling prescription volume.

READ FULL POST

NewLink Insiders Sell Stock While Moss Grows on Pancreatic Cancer Vaccine Analysis

05/05/15 - 10:40 AM EDT

The wait goes on for NewLink Genetics to disclose the second interim analysis from the ongoing phase III study of its pancreatic cancer vaccine.

READ FULL POST

Ariad Pharma CEO 'Retires' in Settlement With Activist Hedge Fund

04/29/15 - 09:01 AM EDT

Sarissa Capital, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger's ouster.

READ FULL POST

Gilead Should Buy Vertex Pharma for $45B Now, Analyst Says

04/21/15 - 07:48 AM EDT

Gilead Sciences should solve its long-term revenue cliff problem by acquiring Vertex Pharmaceuticals and its growing cystic fibrosis drug franchise for $45 billion, says Bernstein analyst Geoff Porges.

READ FULL POST

Juno, Kite CAR-T Stocks Fall on Disappointing Solid Tumor Data

04/20/15 - 10:22 AM EDT

Shares of Juno Therapeutics and Kite Pharma are weak Monday following a lackluster showing for so-called CAR-T cellular therapies in solid tumors at a closely watched cancer conference this weekend.

READ FULL POST

If SpaceX CEO Musk was Biotech CEO, Rocket's 'Landing' Big Win

04/16/15 - 09:07 AM EDT

In which Musk learns how to put a happy spin on failure from biotech CEOs.

READ FULL POST

Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO Debut

04/15/15 - 11:35 AM EDT

Aduro Biotech shares doubled in value Wednesday following a successful initial public offering -- another sign that investor demand for cancer immunotherapy stocks remains strong.

READ FULL POST

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs